Change in population prevalences of human papillomavirus after initiation of vaccination: The high-throughput HPV monitoring study

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 12, 2014, Pages 2757-2764

  Söderlund Strand, Anna ^a   Uhnoo, Ingrid ^b   Dillner, Joakim ^c  

^a Center for Primary Health Care Research   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHLAMYDIA TRACHOMATIS; FEMALE; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; SCREENING; SWEDEN; VACCINATION; WART VIRUS; CHLAMYDIA INFECTIONS; GENETICS; IMMUNOLOGY; PAPILLOMAVIRIDAE; VIROLOGY; YOUNG ADULT;

ADOLESCENT; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; GENOTYPE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMAN PAPILLOMAVIRUS 16; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; YOUNG ADULT;

EID: 84919390466     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0687     Document Type: Article

References (20)

1. Lehtinen M, Paavonen J, Wheeler C.M., Jaisamrarn U., Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 89-99.
2. Munoz N, Kjaer SK, Sigurdsson K, Iversen O.E., Hernandez-Avila M, Wheeler CM, et al Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325-39.
3. Blomberg M, Dehlendorff C, Munk C., Kjaer SK. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013; 57: 929-34.
4. Leval A, Herweijer E, Ploner A, Eloranta S, FridmanSimard J, Dillner J, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst 2013; 105: 469-74.
5. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki H, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE 2013; 8:e68329.
6. Markowitz LE, Tsu V, Deeks S.L., Cubie H., Wang SA, Vicari AS, et al. Human papillomavirus vaccine introduction-the first five years. Vaccine 2012; 30(SUPPL. 5):F139-48.
7. Tegnell A, Dillner J, Andrae B. Introduction of human papillomavirus (HPV) vaccination in Sweden. Euro Surveill 2009; 14:pii 19119.
8. Dillner J, Arbyn M, Unger E., Dillner L. Monitoring of human papillomavirus vaccination. Clin Exp Immunol 2011; 163: 17-25.
9. Tota JE, Ramanakumar AV, Jiang M, Dillner J, Walter SD, Kaufman JS, et al. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol 2013; 178: 625-34.
10. Brown DR, Kjaer SK, Sigurdsson K, Iversen O.E., Hernandez-Avila M, Wheeler CM, et al The impact of quadrivalent human papillomavirus (HPV; types 6,11,16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199: 926-35.
11. Soderlund-Strand A., Dillner J. High-throughput monitoring of human papillomavirus type distribution. Cancer Epidemiol Biomarkers Prev 2013; 22: 242-50.
12. Eklund C, Forslund O, Wallin K.L., Zhou T., Dillner J. The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol 2012; 50: 2289-98.
13. Soderlund-Strand A., Carlson J, Dillner J. Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol 2009; 47: 541-6.
14. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen O.E., Hernandez-Avila M, Perez G, et al The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199: 936-44.
15. Vanska S, Auranen K, Leino T., Salo H, Nieminen P, Kilpi T., et al. Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach. PLoS ONE 2013; 8:e72088.
16. Tabrizi SN, Brotherton JM, Kaldor J.M., Skinner SR, Cummins E, Liu B, et al Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206: 1645-51.
17. Markowitz LE, Hariri S, Lin C., Dunne EF, Steinau M, McQuillan G, et al Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208: 385-93.
18. Mesher D, Soldan K, Howell-Jones R, Panwar K., Manyenga P, Jit M, et al Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013; 32: 26-32.
19. Ramqvist T, Du J, Lunden M., ährlund-Richter S, Ferreira J, Marions L, et al. Pre-vaccination prevalenceofhumanpapillomavirus types in the genital tract of 15-23-year-old women attending a youth health clinic in Stockholm, Sweden. Scand J Infect Dis 2011; 43: 115-21.
20. Malagon T, Drolet M, Boily M.C., Franco EL, Jit M, Brisson J, et al Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 781-9.